BR112013013723A2 - composições e métodos para tratar sintomas associados à plca amilóide - Google Patents

composições e métodos para tratar sintomas associados à plca amilóide

Info

Publication number
BR112013013723A2
BR112013013723A2 BR112013013723A BR112013013723A BR112013013723A2 BR 112013013723 A2 BR112013013723 A2 BR 112013013723A2 BR 112013013723 A BR112013013723 A BR 112013013723A BR 112013013723 A BR112013013723 A BR 112013013723A BR 112013013723 A2 BR112013013723 A2 BR 112013013723A2
Authority
BR
Brazil
Prior art keywords
plca
amyloid
compositions
methods
symptoms associated
Prior art date
Application number
BR112013013723A
Other languages
English (en)
Portuguese (pt)
Inventor
Holtzman David
Kim Jungsu
Jiang Hong
Original Assignee
The Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Washington University filed Critical The Washington University
Publication of BR112013013723A2 publication Critical patent/BR112013013723A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112013013723A 2010-12-02 2011-12-02 composições e métodos para tratar sintomas associados à plca amilóide BR112013013723A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US201161548542P 2011-10-18 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
BR112013013723A2 true BR112013013723A2 (pt) 2019-09-24

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013723A BR112013013723A2 (pt) 2010-12-02 2011-12-02 composições e métodos para tratar sintomas associados à plca amilóide

Country Status (14)

Country Link
US (2) US20140037638A1 (enExample)
EP (1) EP2646053A4 (enExample)
JP (1) JP2014502276A (enExample)
KR (1) KR20140017513A (enExample)
CN (1) CN103338786A (enExample)
AU (1) AU2011336360A1 (enExample)
BR (1) BR112013013723A2 (enExample)
CA (1) CA2819679A1 (enExample)
MX (1) MX2013006116A (enExample)
NZ (1) NZ611614A (enExample)
RU (1) RU2013130002A (enExample)
SG (1) SG190952A1 (enExample)
WO (1) WO2012075422A2 (enExample)
ZA (1) ZA201303996B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
JP6679582B2 (ja) 2014-09-30 2020-04-15 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウの動態測定
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
EP3532034A4 (en) 2016-10-28 2020-12-02 Washington University ANTI-APOE ANTIBODY
CN111093696B (zh) 2017-07-17 2023-10-27 詹森生物科技公司 抗iii型纤连蛋白结构域的抗原结合区及其使用方法
CN114174330B (zh) * 2019-05-28 2025-01-17 总医院公司 Apoe抗体、融合蛋白及其用途
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
CN120787237A (zh) * 2022-11-30 2025-10-14 明尼苏达大学董事会 自然杀伤细胞接合剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE625212T1 (de) * 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
EP2343318A3 (en) * 2003-11-28 2013-02-27 MedImmune Limited Antibodies binding to a C-terminal fragment of apolipoprotein E
US20070160585A1 (en) * 2004-03-30 2007-07-12 Kei Fujinaga Remedy for prion disease and method of producing the same
US20070248599A1 (en) * 2006-02-21 2007-10-25 Jordan Tang Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2542581A4 (en) * 2010-03-01 2014-01-22 David Gladstone Inst APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
KR20140017513A (ko) 2014-02-11
SG190952A1 (en) 2013-07-31
EP2646053A4 (en) 2014-05-28
WO2012075422A3 (en) 2012-10-04
EP2646053A2 (en) 2013-10-09
CA2819679A1 (en) 2012-06-07
ZA201303996B (en) 2015-10-28
US20140037638A1 (en) 2014-02-06
AU2011336360A1 (en) 2013-07-04
MX2013006116A (es) 2013-10-17
CN103338786A (zh) 2013-10-02
JP2014502276A (ja) 2014-01-30
NZ611614A (en) 2015-07-31
US20160355581A1 (en) 2016-12-08
RU2013130002A (ru) 2015-01-10
WO2012075422A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
IL254839A0 (en) S1p modulating agents
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
PT2606372T (pt) Nós e métodos para melhorar posicionamento
BR112014004389A2 (pt) métodos e composições para diagnóstico de lesão renal e insuficiência renal
BR112013014395A2 (pt) evento de soja syht0h2 e composições e métodos para deteção desses
BRPI1010655A2 (pt) novos agentes antienvelhecimento e métodos para identificá-los
BR112014009528A2 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112013033944A2 (pt) combinação sinérgica
BR112015010947A2 (pt) composições e métodos para aumentar o metabolismo energético.
DK2713935T3 (da) Kirurgisk afdækning med adskillelige elementer
BR112013023776A2 (pt) composição e abertura vedada com selante
EP2728157A4 (en) ADSORBENT FOR TANK AND TANK
BR112013013723A2 (pt) composições e métodos para tratar sintomas associados à plca amilóide
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BR112013028818A2 (pt) componente do tipo sem filtro e sem fluxo para filtro
FI20116007L (fi) Serotoniinitason nostaminen ja diagnostisointi
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
PT2683372T (pt) Métodos e composições para o tratamento da hiperuricemia e distúrbios metabólicos associados com a hiperuricemia
BR112013019280A2 (pt) composições wnt e métodos para sua utilização
BR112014004414A2 (pt) composições e métodos para tratar doença neurodegenerativa
BR112013009614A2 (pt) conjugados de pochoxime úteis para o tratamento de patologias relacionadas à hsp90
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
EP2849789A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
IT1399433B1 (it) Struttura elasticizzata e procedimento per realizzare detta struttura elasticizzata

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.